Spero Therapeutics (NASDAQ:SPRO) Announces Earnings Results

Posted by Francis Steltz on Aug 12th, 2026

Spero Therapeutics (NASDAQ:SPRO – Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.01, FiscalAI reports. Spero Therapeutics had a return on equity of 35.58% and a net margin of 24.90%.

Spero Therapeutics Trading Down 3.3%

Shares of NASDAQ:SPRO traded down $0.04 during midday trading on Wednesday, reaching $1.19. 764,858 shares of the company were exchanged, compared to its average volume of 874,169. The business’s fifty day moving average is $1.93 and its two-hundred day moving average is $2.30. Spero Therapeutics has a one year low of $1.08 and a one year high of $3.08. The stock has a market cap of $68.90 million, a PE ratio of 4.96 and a beta of 1.55.

Wall Street Analyst Weigh In

SPRO has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Spero Therapeutics in a research note on Friday, July 17th. Wall Street Zen downgraded Spero Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 16th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Reduce”.

Check Out Our Latest Stock Analysis on SPRO

Institutional Trading of Spero Therapeutics

Several hedge funds have recently bought and sold shares of SPRO. Invesco Ltd. bought a new position in shares of Spero Therapeutics during the 2nd quarter valued at about $43,000. Dimensional Fund Advisors LP purchased a new position in shares of Spero Therapeutics during the third quarter valued at about $55,000. Millennium Management LLC bought a new stake in shares of Spero Therapeutics in the fourth quarter worth about $56,000. Quadrature Capital Ltd bought a new stake in shares of Spero Therapeutics in the fourth quarter worth about $88,000. Finally, Two Sigma Investments LP purchased a new stake in shares of Spero Therapeutics in the third quarter worth about $93,000. Hedge funds and other institutional investors own 25.60% of the company’s stock.

Spero Therapeutics Company Profile

(Get Free Report)

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.